Valuation dashboard for HCW Biologics Inc. (HCWB) with P/E N/A, P/B 0.08, EV/EBITDA -1.60 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
HCW Biologics Inc. operates as a preclinical-stage biopharmaceutical firm, primarily engaged in the discovery and advancement of novel immunotherapies. Its research and development efforts are focused on addressing chronic, low-grade inflammation and a spectrum of age-related diseases.
Analysis Summary
HCW Biologics Inc. reported revenue of $54232 in the most recent fiscal year, growing at a 5-year CAGR of -57.9%.
Trailing-twelve-month margins: gross margin 95.9%, operating margin -91.6%, net margin -73.2%.
At the current price of $2.01, HCWB has negative trailing earnings (P/E not meaningful) and an ROE of -142.16%. Market capitalisation stands at $1M.
Balance sheet quality for HCWB: current ratio of 0.1. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 0.08 |
| EV / EBITDA | -1.60 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-45.71 |
| vs Current Price | -2374.1% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| HCWB | HCW Biologics Inc. | 0.08 | -142.2% | ||
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.6B | 29.76 | 6.46 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $2.01 |
| Market Cap | $1M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -142.16% |
| Return on Invested Capital | -39.28% |
| Return on Assets | -18.39% |
| Gross Margin | 95.91% |
| Operating Margin | -91.57% |
| Net Margin | -73.22% |
Related companies: ACXP · ADIL · APRE · APVO · BCDA · BCLI · CELZ
Explore sector: Healthcare · Biotechnology
More sections of HCWB: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks